- New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant
- Latest data continue to show the benefits of Amplatzer™ Amulet™ LAA Occluder's immediate and complete closure of the LAA compared to Watchman‡
- Findings underscore the importance of innovative, minimally invasive treatment options for people battling complex heart conditions like aortic stenosis and atrial fibrillation
ABBOTT PARK, Ill., Feb. 28, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data for its next-generation Navitor™ transcatheter aortic valve implantation (TAVI) system. Results from the study supported Navitor's recent U.S. Food and Drug Administration (FDA) approval to treat people with severe, symptomatic aortic stenosis who are at high or greater risk for open-heart surgery.